Research programme: anticancer therapeutics - Dekk-Tec

Drug Profile

Research programme: anticancer therapeutics - Dekk-Tec

Alternative Names: HOO-IFOS; HOOI

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dekk-Tec
  • Class Amides; Antineoplastics
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 May 2018 Preclinical development in Cancer is ongoing in USA (unspecified route) (Dekk-Tec pipeline, May 2018)
  • 28 May 2018 Dekk-Tec receives SBIR grant from National Cancer Institute for 4-hydroperoxyifosfamide development in Cancer before May 2018 (Dekk-Tec pipeline, May 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top